ArticleNeurosurgery2026
RAGE Inhibition Reduces Surgery-Induced Cerebral Edema After Glioma Resection.
Article in Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
BACKGROUND AND
objectivesCerebral edema (CE) is a common contributor to neurological decline after brain tumor resection. While corticosteroids are effective in managing CE perioperatively, their use is associated with significant side effects and potential interference with immunotherapeutic efficacy in patients with malignant brain tumors. This study aimed to evaluate the anti-inflammatory effects of 2 inhibitors of the receptor for advanced glycation end products (RAGE)-TTP488 and FPS-ZM1-on CE development after glioma resection in murine models.
methodsMice bearing orthotopic CT-2A gliomas were randomized into 4 treatment groups before undergoing fluorescence-guided microsurgical tumor resection. The groups received perioperative administration (from day -4 to day +7) of TTP488, FPS-ZM1, dexamethasone, or vehicle. Postoperative CE was assessed using serial brain MRI over a 7-day period and quantified using manual segmentation. Neurological function, wound healing, and response to anti-PD-1 immunotherapy were also evaluated. Bulk RNA sequencing was performed to analyze differential gene expression associated with RAGE inhibition.
resultsAcross all groups, CE peaked on postoperative day 2 and subsided by day 7. On postoperative day 1, both TTP488 and FPS-ZM1 significantly reduced CE compared with vehicle (P = .03 for TTP488; P = .03 for FPS-ZM1). Notably, unlike dexamethasone, neither RAGE inhibitor impaired the efficacy of anti-PD-1 immunotherapy. FPS-ZM1 treatment was also associated with improved neurological recovery, enhanced wound healing, and potentiated anti-PD-1 therapy at higher doses.
conclusionRAGE inhibitors effectively reduced postoperative CE to a degree comparable with dexamethasone, without compromising the efficacy of immunotherapy or wound healing. These findings suggest that RAGE inhibition may offer a promising steroid-sparing strategy for perioperative management of CE in patients with brain tumor undergoing immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.